Cystic Fibrosis Foundation

Owlstone Medical, established in 2003 and headquartered in Cambridge, UK, specializes in developing and commercializing breathalyzers for clinical diagnostics and precision medicine. The company's core technology, FAIMS, enables the detection of volatile organic compounds (VOCs) in breath, serving as biomarkers for various diseases. Owlstone Medical's product portfolio includes breath samplers like ReCIVA, disease biomarker detection tools such as Lonestar, and advanced mass spectrometry solutions like UltraFAIMS. These products are employed in the diagnosis and monitoring of conditions like lung cancer, asthma, and gastrointestinal disorders. The company collaborates with market leaders to integrate its technology into next-generation chemical sensing products and has received funding from the UK's Department of Defense to develop a handheld device for enhanced chemical detection. Through its subsidiary, Owlstone Medical, the company aims to lead the global market in non-invasive diagnostics for cancer, infectious, and inflammatory diseases, with a focus on breath-based diagnostic tools.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its proprietary Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aiming to restore normal genetic function and address the underlying causes of various diseases. By targeting a broad spectrum of conditions with significant unmet medical needs, Prime Medicine seeks to revolutionize the field of genetic medicine through effective and efficient therapeutic solutions.

Clarametyx Biosciences, Inc. is a biotechnology company based in Columbus, Ohio, focused on developing targeted and immune-enabling biologic therapies to address persistent infections linked to biofilms. Founded in 2020, the company utilizes a novel technology platform designed to penetrate the protective layers surrounding bacteria, facilitating immune responses and enhancing the effectiveness of antibiotic interventions. Among its key developments is CMTX-001, a humanized monoclonal antibody currently in preclinical stages aimed at treating hospital-acquired pneumonia. Clarametyx's innovative approach seeks to combat life-threatening infections while addressing the growing concerns of antibiotic resistance.

ViaNautis is focused on creating innovative medications that can effectively cross biological barriers, particularly the blood-brain barrier (BBB). The company utilizes PolyNaut, a versatile nano-engineered polymer technology, to enhance intracellular delivery of therapeutics. Through the development of nanoparticle technology, ViaNautis encapsulates various therapeutic modalities within polymer nanovesicles, allowing for selective targeting of different tissues and cell types. This approach significantly improves the therapeutic efficacy of the delivered molecules, enabling clients to achieve better treatment outcomes. With partners like SomaServe, ViaNautis is paving the way for advanced medications that offer substantial therapeutic benefits by overcoming various biological barriers.

Arcturus Therapeutics is an RNA medicines company based in San Diego, California, founded in 2013. It specializes in the discovery and development of novel RNA therapeutics aimed at treating rare diseases, particularly in the areas of liver and respiratory care. The company leverages its proprietary Self-Transcribing and Replicating RNA (STARR) technology and Unlocked Nucleic Acid (UNA) chemistry to create RNA drug substances and nanoparticle-formulated products. Arcturus's pipeline includes several preclinical and clinical programs, such as LUNAR-OTC for ornithine transcarbamylase deficiency, LUNAR-CF for cystic fibrosis, and LUNAR-COV19, a vaccine candidate targeting the Coronavirus outbreak. The company holds a robust patent portfolio, encompassing 182 patents and applications globally, enabling it to target any gene in the human genome. Furthermore, Arcturus has established collaborations with various pharmaceutical partners to advance its therapeutic candidates across multiple disease indications.

Nanite is a biotechnology company focused on non-viral gene delivery through the development of programmable polymer nanoparticles. Utilizing an artificial intelligence-driven platform, Nanite combines advanced high-throughput experimental and computational methods to create tailored delivery vehicles. These vehicles are designed to effectively transport a wide range of genetic materials with specific targeting capabilities, facilitating research in functional chemistry and enhancing the design of therapeutically relevant gene delivery systems.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

ReCode Therapeutics, Inc. is a biopharmaceutical company focused on developing precision medicines for pulmonary diseases, particularly targeting genetic conditions such as primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 and based in Menlo Park, California, the company utilizes a groundbreaking selective organ targeting (SORT) lipid nanoparticle platform. This innovative technology facilitates the precise delivery of genetic therapies, including mRNA and gene correction therapeutics, to specific organs and cells beyond the liver. By overcoming limitations of traditional gene therapy approaches, ReCode Therapeutics aims to address the needs of patients with rare and life-limiting respiratory diseases, thus providing new treatment options for those affected by genetic disorders.

Gensaic is a biotechnology company focused on advancing genomic medicine through its innovative bacteriophage-based platform. This platform is designed to address significant limitations in traditional gene therapy by enabling durable therapeutic efficacy through repeat administration. Gensaic's technology allows for tissue-specific targeting and supports scalable manufacturing processes, making it easier to deliver gene therapies effectively to human cells. The company's mission is to reimagine gene therapy, aiming to create impactful solutions for human diseases and contribute to the scientific advancement in the field of genomic medicines.

Aridis Pharmaceuticals is a late-stage biopharmaceutical company based in San Jose, California, founded in 2003. The company specializes in discovering and developing targeted immunotherapy treatments using fully human monoclonal antibodies (mAbs) to combat life-threatening infections. Its lead product candidate, AR-301, is currently in Phase III trials for treating lung infections caused by S. aureus alphatoxin. Additionally, Aridis Pharmaceuticals is advancing several other mAb candidates through various stages of clinical development, including AR-105 and AR-101 for gram-negative bacterial infections, AR-401 for Acinetobacter baumannii infections, AR-201 for respiratory syncytial virus, and AR-501 for chronic lung infections in cystic fibrosis patients. The company employs proprietary technology platforms to rapidly identify and manufacture these mAbs from patients who have successfully overcome infections, leveraging the natural potency of the human immune system.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Carmine Therapeutics, established in 2019 and headquartered in Singapore, specializes in gene therapy. It produces extracellular vesicles from red blood cells as a non-viral, re-dosable gene delivery vehicle, addressing challenges posed by traditional viral-based therapies such as immunogenicity, limited transgene capacity, and manufacturing complexities. The company focuses on developing next-generation gene therapies for hematology, oncology, and immunology.

Destiny Pharma is a clinical-stage biotechnology company based in Brighton, United Kingdom, specializing in the discovery and development of innovative antimicrobial medicines aimed at treating infectious diseases. The company is advancing several drug candidates, including XF-73 Nasal, currently in Phase II trials for preventing post-surgical staphylococcal infections, and XF-73 Dermal, which is in Phase I trials for treating skin infections caused by antibiotic-resistant bacteria. Additionally, Destiny Pharma is developing XF-70 for conditions such as ventilator-associated pneumonia and cystic fibrosis, along with DPD-207 for bacterial and fungal eye infections. The company collaborates with various academic institutions and organizations, including the University of Southampton and China Medical System Holdings Limited, to explore new treatments for infections associated with antibiotic resistance. Destiny Pharma's focus on unique mechanisms of action for its XF series presents potential solutions in addressing the growing global healthcare challenge of drug-resistant bacteria.

Carbon Biosciences focuses on developing genetic medicines to address serious diseases. The company utilizes a proprietary platform that employs novel parvoviruses, which are designed to target specific tissues and carry larger therapeutic cargo. This approach minimizes the risk of neutralizing immunity and allows for repeat dosing, making it particularly effective for conditions such as cystic fibrosis, where targeting lung and upper airway tissues is crucial. By leveraging industrial-scale viral production platforms, Carbon Biosciences aims to extend the reach of gene therapies, offering innovative solutions for researchers and patients alike.

Sionna Therapeutics was formed in late 2019, leveraging 10 years of large pharma scientific investment and expertise. Our experienced scientific team has been on a mission to fully normalize CFTR function. In the three decades since the discovery of the genetic defects that cause cystic fibrosis (CF), researchers have made remarkable advances for patients. Yet the ultimate goal of CF drug development – to fully normalize the function of CFTR, the key protein leading to the pathology of CF – has remained out of reach.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Felix Biotechnology, founded in 2019 and based in San Francisco, California, is focused on developing biotherapeutics aimed at addressing microbial challenges in human health, particularly antibiotic-resistant strains of bacteria and fungi. The company aims to accelerate the deployment of innovative treatments for infectious diseases, enabling healthcare professionals to manage these urgent health threats effectively. Through its targeted approach, Felix Biotechnology seeks to provide precise and effective solutions to combat the growing issue of antibiotic resistance.

Feldan Therapeutics is a biopharmaceutical company focused on developing innovative treatments using its proprietary peptide-based technology platform, known as the Feldan Shuttle. This platform facilitates fast and safe intracellular delivery, allowing access to cellular components that are typically unreachable by conventional drugs. By leveraging the unique characteristics of the Feldan Shuttle, the company aims to create a new generation of therapeutic applications, as evidenced by its ongoing pipeline of clinical programs. Feldan Therapeutics is committed to advancing the field of intracellular therapeutics to improve patient outcomes.

SalioGen Therapeutics is a biotechnology company focused on developing gene therapies for inherited disorders. Utilizing its proprietary Exact DNA Integration Technology (EDIT), the company employs mammal-derived enzymes, known as Saliogase, to facilitate genome engineering. This innovative approach enables the delivery of any size gene through non-viral methods, offering significant advantages in manufacturing and application. SalioGen's technology aims to provide durable, safe, and affordable treatments, potentially transforming the landscape of care for patients with genetic conditions and enhancing the efficiency of cell therapy and biologics manufacturing in the healthcare sector.

Peptilogics, Inc. is a biotechnology company based in West Mifflin, Pennsylvania, that focuses on developing novel peptide therapeutics to combat multidrug-resistant bacterial infections. Established in 2013, Peptilogics employs a unique computational platform that facilitates drug discovery by exploring new chemical design spaces and ensuring the biological viability and manufacturability of potential therapeutics. The company's lead candidate, PLG0206, is a broad-spectrum anti-infective peptide that has received FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation, targeting prosthetic joint infections, which represent a significant unmet medical need. Peptilogics aims to provide effective solutions to address the challenges posed by resistant bacteria and biofilms, ultimately improving treatment outcomes for patients.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

EnBiotix, Inc. is a bioengineering company that specializes in developing therapies for chronic and recurrent pulmonary infections, particularly those caused by drug-resistant bacteria. Founded in 2010 and headquartered in Boston, Massachusetts, the company employs innovative platforms, including an anti-persisters platform that enhances antibiotic effectiveness, an engineered bacteriophage platform that targets infections, and a tunable target degradation platform that modifies protein functions. EnBiotix has a diverse clinical pipeline, with notable products such as EBX-001 for P. aeruginosa infections in cystic fibrosis patients, EBX-002 for catheter-associated urinary tract infections, and EPP-001 for prosthetic joint infections. The company's mission is to combat the global rise of antibiotic resistance by revitalizing existing antibiotic classes and addressing a significant market need for effective treatments in the healthcare landscape.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Armata Pharmaceuticals is a clinical-stage biotechnology company headquartered in Marina del Rey, California, specializing in the development of targeted bacteriophage therapeutics for addressing drug-resistant bacterial infections. Founded in 2005, the company aims to combat the rising threat of multidrug-resistant bacteria, which has been exacerbated by antibiotic overuse and poses significant health risks. Armata focuses on creating pathogen-specific bacteriophage therapies, leveraging both natural and synthetic phage candidates to effectively treat infections caused by bacteria such as Pseudomonas aeruginosa and Staphylococcus aureus. The company is advancing a diverse pipeline of therapeutic candidates and is collaborating with Merck to develop proprietary synthetic phage therapies for specific infectious disease agents.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Metagenomi, Inc. is a biotechnology company focused on developing gene editing systems aimed at treating genetic diseases. Founded in 2016 and based in Emeryville, California, Metagenomi utilizes metagenomics and machine learning to uncover novel genome editing technologies derived from previously uncharacterized organisms. The company's innovative discovery platform enables the creation of highly efficient and specific gene editing tools, including programmable nucleases, base editors, and advanced integration systems such as prime editing and CRISPR-associated transposases. By harnessing these naturally evolved systems, Metagenomi seeks to address a wide range of genetic mutations that traditional genome engineering approaches have struggled to target, with the ultimate goal of providing transformative therapies for patients globally.

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations. The company has developed a compound to cure the lung disease in cystic fibrosis patients carrying a specific splicing mutation. It is also developing a targeted modulation approach to correct the splicing pattern of CFTR transcripts according to the specific mutation carried.

Microbion Corporation is a biopharmaceutical company focused on developing therapeutics for resistant and difficult-to-treat infections. Founded in 1982 and headquartered in Bozeman, Montana, with an additional office in Vancouver, Canada, the company specializes in bismuth-thiols, which are designed to prevent microbial biofilms from forming on implanted medical devices and to manage biofilms in various infectious diseases. Microbion's product pipeline includes treatments for chronic and acute wound infections, particularly those related to diabetic foot ulcers, orthopedic implant-related infections, and other chronic wounds. The company also addresses the challenges posed by antibiotic-resistant microbes, including methicillin-resistant staphylococcus aureus, and aims to reduce infections associated with military wounds.

Kinnear Pharmaceuticals is a preclinical stage pharmaceutical company committed to the discovery, development and commercialization of ceragenin-based anti-infective and anti-inflammatory product candidates for diseases with large unmet clinical needs.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Spexis AG is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, specializing in the discovery and development of macrocycle drugs and antibiotics to address severe or life-threatening diseases. Founded in 1996, the company focuses on addressing high unmet medical needs, particularly in the areas of antibiotic resistance and respiratory diseases. Spexis's lead product, murepavadin, is currently in Phase III development targeting Pseudomonas aeruginosa, a pathogen identified as a critical priority by the World Health Organization. The company's operations are centered on research, development, and the prospective commercialization of innovative therapeutics in the respiratory domain.

Calithera Biosciences is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing small molecule drugs targeting tumor metabolism and immunology for cancer treatment. The company's lead candidate, CB-839, is a glutaminase inhibitor currently in Phase II clinical trials aimed at treating solid tumors. Additionally, Calithera is advancing INCB001158, an oral arginase inhibitor in Phase I/II trials for hematology and oncology. Other notable projects include CB-280, intended for cystic fibrosis treatment, and CB-708, an inhibitor of CD73. The company has established collaborations, including a license agreement with Mars, Inc. for the development of arginase inhibitors and a clinical trial partnership with Bristol-Myers Squibb to evaluate nivolumab in combination with CB-839. Founded in 2010, Calithera is focused on building a pipeline of innovative cancer therapeutics that address critical pathways necessary for tumor growth and survival.

enGene, Inc. is a biotechnology company specializing in mucosal immunotherapy platforms aimed at treating inflammatory bowel disease and diabetes. The company has developed a non-integrating biopolymer-based nucleotide delivery technology that enables localized delivery of immune-modulating proteins to mucosal tissues, including the gastrointestinal tract, lung, and bladder. This innovative approach allows for the treatment of various immune disorders and supports systemic release of proteins from the gut to address conditions such as diabetes, anemia, and hemophilia. Founded in 1999 and based in Vancouver, Canada, enGene has formed a strategic alliance with Takeda Pharmaceutical Company Ltd. The company's platform facilitates the induction or suppression of protein expression levels, which can help regenerate physiologic, meal-regulated insulin secretion for diabetes patients.

Synspira Therapeutics is focused on developing a rationally designed portfolio of products in cystic fibrosis and other rare diseases. Inspired by patients and frustrated by the limitations of conventional treatments, Synspira is advancing two novel products (SNSP113 and SNSP003) in order to provide better clinical outcomes and reduce treatment burden in Progressive Pulmonary Disease and Malabsorption Syndromes.

4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing innovative gene therapy products to address unmet medical needs. The company utilizes targeted and evolved adeno-associated virus vectors to create a diverse portfolio of product candidates focused on ophthalmology, cardiology, and pulmonology. Among its key projects are 4D-125, currently in a Phase I/II clinical trial for X-linked retinitis pigmentosa; 4D-110, in a Phase I clinical trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is advancing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. Founded in 2013, the company is dedicated to transforming the treatment landscape in these therapeutic areas.

Microbion Corporation is a biopharmaceutical company focused on developing therapeutics for resistant and difficult-to-treat infections. Founded in 1982 and headquartered in Bozeman, Montana, with an additional office in Vancouver, Canada, the company specializes in bismuth-thiols, which are designed to prevent microbial biofilms from forming on implanted medical devices and to manage biofilms in various infectious diseases. Microbion's product pipeline includes treatments for chronic and acute wound infections, particularly those related to diabetic foot ulcers, orthopedic implant-related infections, and other chronic wounds. The company also addresses the challenges posed by antibiotic-resistant microbes, including methicillin-resistant staphylococcus aureus, and aims to reduce infections associated with military wounds.

Crestone is a clinical-stage biopharmaceutical company focused on developing novel small molecule drugs for serious bacterial infections. Its research pipeline includes treatments for Clostridium difficile, antibiotic-resistant Gram-positive infections, and tuberculosis. The company aims to address significant unmet medical needs by utilizing innovative mechanisms in its drug candidates, which are designed to disrupt the cycle of bacterial growth and resistance. Through its efforts, Crestone seeks to enhance treatment outcomes for patients dealing with these challenging infections.

Laurent Pharmaceuticals Inc. is a private biopharmaceutical company based in Montreal, Canada, focused on developing orally-active drug candidates aimed at modulating the immuno-inflammatory response in cystic fibrosis patients. The company's lead product, LAU-7b, is a novel once-a-day oral formulation of fenretinide, designed to address the compromised immune-inflammatory response associated with cystic fibrosis, a condition that can lead to significant pulmonary insufficiency. Founded in 2012, Laurent Pharmaceuticals is in the clinical stage of drug development, working to provide innovative treatment options for this complex disease.

Enterprise Therapeutics, established in 2014 and headquartered in Brighton, UK, is a drug discovery company focused on developing therapies for respiratory diseases. Its primary focus is on chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company aims to create novel treatments that target the underlying mechanisms of mucus congestion, reducing lung infections and enhancing patients' quality of life.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts, specializing in the development of novel drugs targeting rare and ultra-rare genetic diseases caused by nonsense mutations. Founded in 2013, the company is focused on discovering and commercializing ribonucleic acid modulating drug candidates. Its lead investigational product, ELX-02, is currently undergoing Phase 2 clinical trials aimed at treating cystic fibrosis and nephropathic cystinosis in patients with specific nonsense mutations. Eloxx utilizes its advanced technology platform to create oral small molecules that can induce ribosomal readthrough, thereby enabling the production of full-length functional proteins. The company is building a robust pipeline of therapeutic candidates designed to address various genetic disorders, including Duchenne Muscular Dystrophy and Tay-Sachs syndrome, by overcoming the limitations posed by premature stop codons.

Celtaxsys, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for inflammatory diseases, cancer, and autoimmune disorders. Established in 2007 and headquartered in Atlanta, Georgia, the company is engaged in developing drug compounds that manipulate immune cell migration and activation. One of its key products, CTX-4430, is a small-molecule drug designed to inhibit the enzyme Leukotriene A4 hydrolase in immune cells, targeting conditions such as cystic fibrosis and moderately severe acne. Celtaxsys aims to provide innovative treatments that address the protective mechanisms of certain tumors, thereby enhancing the immune response against cancer and managing serious inflammatory conditions.

Spirovant Sciences, Inc. is a biotechnology company based in Philadelphia, Pennsylvania, focused on developing gene therapies for cystic fibrosis and related pulmonary diseases. Founded in 2016, the company aims to address historical challenges in effectively treating these conditions through innovative gene therapy technologies. Spirovant's platforms utilize adeno-associated viral and lentiviral vectors to carry large genetic payloads, enabling more effective treatment options for patients. As a subsidiary of Sumitovant Biopharma Ltd., Spirovant is dedicated to changing the course of cystic fibrosis and improving outcomes for those affected by this disease.

Vast Therapeutics is a preclinical-stage pharmaceutical company based in Durham, North Carolina, focused on developing inhalable treatments for antibiotic-resistant pathogens affecting patients with cystic fibrosis and other respiratory diseases. Founded in 2017 and originally known as Novoclem Therapeutics, the company aims to address chronic infections prevalent among the cystic fibrosis population. Vast Therapeutics operates as a subsidiary of KNOW Bio, LLC, and is dedicated to advancing innovative therapeutic solutions for individuals facing these challenging health conditions.

Aridis Pharmaceuticals is a late-stage biopharmaceutical company based in San Jose, California, founded in 2003. The company specializes in discovering and developing targeted immunotherapy treatments using fully human monoclonal antibodies (mAbs) to combat life-threatening infections. Its lead product candidate, AR-301, is currently in Phase III trials for treating lung infections caused by S. aureus alphatoxin. Additionally, Aridis Pharmaceuticals is advancing several other mAb candidates through various stages of clinical development, including AR-105 and AR-101 for gram-negative bacterial infections, AR-401 for Acinetobacter baumannii infections, AR-201 for respiratory syncytial virus, and AR-501 for chronic lung infections in cystic fibrosis patients. The company employs proprietary technology platforms to rapidly identify and manufacture these mAbs from patients who have successfully overcome infections, leveraging the natural potency of the human immune system.

Laurent Pharmaceuticals Inc. is a private biopharmaceutical company based in Montreal, Canada, focused on developing orally-active drug candidates aimed at modulating the immuno-inflammatory response in cystic fibrosis patients. The company's lead product, LAU-7b, is a novel once-a-day oral formulation of fenretinide, designed to address the compromised immune-inflammatory response associated with cystic fibrosis, a condition that can lead to significant pulmonary insufficiency. Founded in 2012, Laurent Pharmaceuticals is in the clinical stage of drug development, working to provide innovative treatment options for this complex disease.

Icagen, Inc. is a biopharmaceutical company based in Durham, North Carolina, specializing in drug discovery with a particular emphasis on neuroscience and rare diseases. Founded in 2003, the company focuses on developing novel orally-administered small molecule drugs that target ion channels, among other therapeutic areas. Icagen provides a range of pre-clinical drug discovery services, including assay development, cell line generation, high-throughput screening, medicinal and computational chemistry, and custom assay services. The company's drug pipeline includes ICA-105665, currently in Phase I trials for epilepsy and neuropathic pain, and Senicapoc, which is undergoing Phase I studies for asthma. Icagen actively collaborates with major pharmaceutical companies, such as Bristol-Myers Squibb, Astellas Pharma, and Pfizer, to advance its research and development initiatives.

Laurent Pharmaceuticals Inc. is a private biopharmaceutical company based in Montreal, Canada, focused on developing orally-active drug candidates aimed at modulating the immuno-inflammatory response in cystic fibrosis patients. The company's lead product, LAU-7b, is a novel once-a-day oral formulation of fenretinide, designed to address the compromised immune-inflammatory response associated with cystic fibrosis, a condition that can lead to significant pulmonary insufficiency. Founded in 2012, Laurent Pharmaceuticals is in the clinical stage of drug development, working to provide innovative treatment options for this complex disease.

Synspira Therapeutics is focused on developing a rationally designed portfolio of products in cystic fibrosis and other rare diseases. Inspired by patients and frustrated by the limitations of conventional treatments, Synspira is advancing two novel products (SNSP113 and SNSP003) in order to provide better clinical outcomes and reduce treatment burden in Progressive Pulmonary Disease and Malabsorption Syndromes.

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection, and in preparation for Phase 2a development in cystic fibrosis, or CF, affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin resistant staphylococcus aureus, or MRSA, lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. The most recent acquisition is aerosolized amikacin/fosfomycin, a Phase 2 ready, proprietary combination antibiotic, which has demonstrated potent and broad-spectrum antibacterial activity against highly drug resistant pathogens. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

4D Molecular Therapeutics is a clinical-stage gene therapy company based in Emeryville, California, that specializes in developing innovative gene therapy products to address unmet medical needs. The company utilizes targeted and evolved adeno-associated virus vectors to create a diverse portfolio of product candidates focused on ophthalmology, cardiology, and pulmonology. Among its key projects are 4D-125, currently in a Phase I/II clinical trial for X-linked retinitis pigmentosa; 4D-110, in a Phase I clinical trial for choroideremia; and 4D-310, also in a Phase I/II trial for Fabry disease. Additionally, 4D Molecular Therapeutics is advancing investigational new drug candidates such as 4D-150 for wet age-related macular degeneration and 4D-710 for cystic fibrosis lung disease. Founded in 2013, the company is dedicated to transforming the treatment landscape in these therapeutic areas.

Sound Pharmaceuticals, Inc. is a biopharmaceutical company based in Seattle, Washington, that specializes in developing neurotologic drugs aimed at treating sensorineural diseases of the inner ear. Established in 2001, the company focuses on creating prescription medications that help prevent and treat hearing loss. Its innovative platform works by developing compounds that antagonize growth inhibitory proteins, allowing normally non-dividing epithelial cells in the inner ear to divide and potentially become replacement auditory hair cells. This process, which does not occur naturally in humans after birth, offers a new approach to addressing various forms of hearing loss in a cost-effective manner.

Aridis Pharmaceuticals is a late-stage biopharmaceutical company based in San Jose, California, founded in 2003. The company specializes in discovering and developing targeted immunotherapy treatments using fully human monoclonal antibodies (mAbs) to combat life-threatening infections. Its lead product candidate, AR-301, is currently in Phase III trials for treating lung infections caused by S. aureus alphatoxin. Additionally, Aridis Pharmaceuticals is advancing several other mAb candidates through various stages of clinical development, including AR-105 and AR-101 for gram-negative bacterial infections, AR-401 for Acinetobacter baumannii infections, AR-201 for respiratory syncytial virus, and AR-501 for chronic lung infections in cystic fibrosis patients. The company employs proprietary technology platforms to rapidly identify and manufacture these mAbs from patients who have successfully overcome infections, leveraging the natural potency of the human immune system.

Laurent Pharmaceuticals Inc. is a private biopharmaceutical company based in Montreal, Canada, focused on developing orally-active drug candidates aimed at modulating the immuno-inflammatory response in cystic fibrosis patients. The company's lead product, LAU-7b, is a novel once-a-day oral formulation of fenretinide, designed to address the compromised immune-inflammatory response associated with cystic fibrosis, a condition that can lead to significant pulmonary insufficiency. Founded in 2012, Laurent Pharmaceuticals is in the clinical stage of drug development, working to provide innovative treatment options for this complex disease.

Laurent Pharmaceuticals Inc. is a private biopharmaceutical company based in Montreal, Canada, focused on developing orally-active drug candidates aimed at modulating the immuno-inflammatory response in cystic fibrosis patients. The company's lead product, LAU-7b, is a novel once-a-day oral formulation of fenretinide, designed to address the compromised immune-inflammatory response associated with cystic fibrosis, a condition that can lead to significant pulmonary insufficiency. Founded in 2012, Laurent Pharmaceuticals is in the clinical stage of drug development, working to provide innovative treatment options for this complex disease.

Corbus Pharmaceuticals is a clinical-stage pharmaceutical company based in Norwood, Massachusetts, that focuses on developing and commercializing therapeutics for inflammatory and fibrotic diseases. Founded in 2009, the company’s lead product candidate, lenabasum, is a synthetic oral CB2 agonist currently undergoing Phase III clinical trials for systemic sclerosis and dermatomyositis, and Phase IIb trials for systemic lupus erythematosus and cystic fibrosis. In addition to lenabasum, Corbus is developing CRB-4001, a peripherally-restricted CB1 inverse agonist aimed at treating nonalcoholic steatohepatitis and other fibrotic conditions. The company is leveraging a diverse pipeline of drug candidates sourced from a library of over 600 novel compounds targeting the endocannabinoid system. Furthermore, Corbus has established collaborations for the development and commercialization of its products, including a partnership with Kaken Pharmaceutical Co., Ltd. for lenabasum in Japan.

Parion Sciences is a development stage company focused on researching, developing, and commercializing treatments aimed at restoring the innate mucosal surface defenses in patients. The company's innovative technologies specifically target diseases affecting the respiratory and ocular systems, where the protective mucus layer is compromised due to factors such as genetics, aging, or environmental influences. By addressing these unmet medical needs, Parion Sciences seeks to enhance the health and well-being of individuals suffering from conditions related to weakened mucosal defenses.

Corus Pharma is a biotech and specialty drug company that focuses on respiratory and infectious diseases. In other words, it is a development stage biopharmaceutical company that focuses on the development and commercialization of novel applications and formulations of known therapeutics to treat severe respiratory diseases. The products of the company are Corus 1020 and 1030. Corus 1020 is designed to treat respiratory infections in cystic fibrosis patients, using an inhalable form of an antibiotic called aztreonam. Corus 1030 is inhaled lidocaine for the treatment of patients suffering from the severe persistent forms of asthma. Corus Pharma is a U.S.-based company that was founded in 2001 and the company was acquired by Gilead Sciences on October 22, 2006.

Altus Pharmaceuticals is an information technology consulting firm that serves a diverse range of clients, including healthcare providers, manufacturing companies, and financial institutions. The firm positions itself as a strategic partner, providing expertise to help organizations navigate complex challenges and enhance their operational efficiency. With a focus on delivering impactful solutions, Altus aims to support its clients in achieving their goals while addressing the unique demands of their respective industries.